Literature DB >> 9892138

Angiotensin II receptors.

R Ardaillou1.   

Abstract

This review examines the recent progress in the field of angiotensin receptors. Multiplicity of these receptors was demonstrated initially on the basis of pharmacologic differences and then confirmed by expression cloning. AT1 receptors are predominant in the adult. They are widely distributed and mediate all of the known biologic effects of angiotensin II (AngII) through a variety of signal transduction systems, including activation of phospholipases C and A2, inhibition of adenylate cyclase, opening of calcium channels, and activation of tyrosine kinases. AT2 receptors are predominant in the fetus, but also present in adult tissues such as the adrenals, ovaries, uterus, and brain. AngII via these receptors exerts effects often opposed to those mediated by the AT1 receptors. Signal transduction implicates protein tyrosine phosphatase stimulation. AT1 and AT2 receptor expressions are regulated differently, and regulation is also tissue-specific. AT1 and AT2 receptors have been demonstrated in endothelial cells. Activation of AT1 receptors results in production of vasodilatory agents, nitric oxide, and prostacyclin (PGI2), which counteract the direct vasoconstrictor effects of Ang II on the adjacent smooth muscle cells. AT1 receptors on mesangial cells, smooth muscle cells, and fibroblasts are involved in cell growth and fibrosis, the latter being due both to an increase in the synthesis and a decrease in the degradation of the main components of the extracellular matrix. These AT1 receptor-dependent effects are for the most part indirect and mediated by growth factors, cytokines, and other peptides, including endothelin, transforming growth factor-beta1, and platelet-derived growth factor. AngII is metabolized into active fragments by deletion of the terminal amino acids on both ends. AngIII and AngIV are formed by successive deletions of aspartic acid and arginine at the N terminus. AngII (1-7) is obtained by deletion of phenylalanine at the C terminus. AngIII shares the same receptors and exerts the same effects as AngII. AngIV and AngII (1-7) recognize the AT1 and AT2 receptors with a lesser affinity than AngII and, in addition, possess their own receptors that mediate effects often opposed to those of AngII.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892138

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  22 in total

Review 1.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

2.  Altered renin-angiotensin system gene expression causes renal hypoplasia in the rats with nitrofen-induced diaphragmatic hernia.

Authors:  Boris Chertin; Nana Nakazawa; Sandra Montedonico; Hideki Shima; Prem Puri
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

3.  Angiotensin receptor blockers for heart failure.

Authors:  Phillip Jong; Catherine Demers; Robert S McKelvie; Peter Liu
Journal:  Cochrane Database Syst Rev       Date:  2001

4.  Maternal caffeine administration leads to adverse effects on adult mice offspring.

Authors:  Diana F Serapiao-Moraes; Vanessa Souza-Mello; Marcia B Aguila; Carlos A Mandarim-de-Lacerda; Tatiane S Faria
Journal:  Eur J Nutr       Date:  2013-01-05       Impact factor: 5.614

Review 5.  Update: role of the angiotensin type-2 (AT(2)) receptor in blood pressure regulation.

Authors:  R M Carey; Z Q Wang; H M Siragy
Journal:  Curr Hypertens Rep       Date:  2000-04       Impact factor: 5.369

6.  Spectrum of use for the angiotensin-receptor blocking drugs.

Authors:  M E Fabiani; C I Johnston
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

7.  Pomc knockout mice have secondary hyperaldosteronism despite an absence of adrenocorticotropin.

Authors:  Kirsten-Berit Linhart; Joseph A Majzoub
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

8.  Network modeling reveals steps in angiotensin peptide processing.

Authors:  John H Schwacke; John Christian G Spainhour; Jessalyn L Ierardi; Jose M Chaves; John M Arthur; Michael G Janech; Juan Carlos Q Velez
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

Review 9.  RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.

Authors:  Jay Lakkis; Wei X Lu; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

Review 10.  The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis.

Authors:  Sungchun Lee; Sohee Lee; Kumar Sharma
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.